Evidence map›Paper›PMID 25216266›Full record

ArticlePloS one2014

ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.

Erhong Meng, Aparna Mitra, Kaushlendra Tripathi, Michael A Finan, Jennifer Scalici, Steve McClellan, Luciana Madeira da Silva, Eddie Reed, Lalita A Shevde, Komaraiah Palle and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 169 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Exploiting Matrix Stiffness to Overcome Drug Resistance.ACS biomaterials science & engineering · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Erhong MengUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States of America.
Aparna MitraUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States of America.
Kaushlendra TripathiUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States of America.
Michael A FinanUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States of America.
Jennifer ScaliciUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States of America.
Steve McClellanUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States of America.
Luciana Madeira da SilvaUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States of America.
Eddie ReedNational Institutes of Health, National Institute on Minority Health and Health Disparities, Bethesda, Maryland, United States of America.
Lalita A ShevdeUniversity of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Komaraiah PalleUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States of America.
Rodney P RocconiUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States of America.
USA Mitchell Cancer Institute · USUniversity of South Alabama · USNational Institutes of Health · USUniversity of Alabama at Birmingham · US

Funding

Ras18-mediated Fanconi Anemia pathway activation in response to camptothecinR01GM098956 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PALLE, KOMARAIAH · 2012 to 2016
$1.1M
NIGMS NIH HHS R01 GM098956NIGMS NIH HHS R01GM098956
6 · The paper itself

Abstract

objectiveAldehyde dehydrogenase (ALDH) expressing cells have been characterized as possessing stem cell-like properties. We evaluated ALDH+ ovarian cancer stem cell-like properties and their role in platinum resistance.

methodsIsogenic ovarian cancer cell lines for platinum sensitivity (A2780) and platinum resistant (A2780/CP70) as well as ascites from ovarian cancer patients were analyzed for ALDH+ by flow cytometry to determine its association to platinum resistance, recurrence and survival. A stable shRNA knockdown model for ALDH1A1 was utilized to determine its effect on cancer stem cell-like properties, cell cycle checkpoints, and DNA repair mediators.

resultsALDH status directly correlated to platinum resistance in primary ovarian cancer samples obtained from ascites. Patients with ALDHHIGH displayed significantly lower progression free survival than the patients with ALDHLOW cells (9 vs. 3 months, respectively p<0.01). ALDH1A1-knockdown significantly attenuated clonogenic potential, PARP-1 protein levels, and reversed inherent platinum resistance. ALDH1A1-knockdown resulted in dramatic decrease of KLF4 and p21 protein levels thereby leading to S and G2 phase accumulation of cells. Increases in S and G2 cells demonstrated increased expression of replication stress associated Fanconi Anemia DNA repair proteins (FANCD2, FANCJ) and replication checkpoint (pS317 Chk1) were affected. ALDH1A1-knockdown induced DNA damage, evidenced by robust induction of γ-H2AX and BAX mediated apoptosis, with significant increases in BRCA1 expression, suggesting ALDH1A1-dependent regulation of cell cycle checkpoints and DNA repair networks in ovarian cancer stem-like cells.

conclusionThis data suggests that ovarian cancer cells expressing ALDH1A1 may maintain platinum resistance by altered regulation of cell cycle checkpoint and DNA repair network signaling.

Indexed as

Cell Cycle CheckpointsDNA RepairSignal TransductionAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyCell Line, TumorCyclin-Dependent Kinase Inhibitor p21Disease-Free SurvivalDown-RegulationDrug Resistance, NeoplasmFemaleGene Knockdown TechniquesHumansIsoenzymesKruppel-Like Factor 4Kruppel-Like Transcription FactorsAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanCyclin-Dependent Kinase Inhibitor p21IsoenzymesKLF4 protein, humanKruppel-Like Factor 4Kruppel-Like Transcription FactorsPlatinumRetinal Dehydrogenase

Identifiers

PMID25216266
PMCPMC4162571
OpenAlexW2069267879

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.